380 related articles for article (PubMed ID: 30635421)
1. Crystal structure of the WD40 domain dimer of LRRK2.
Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
[TBL] [Abstract][Full Text] [Related]
2. How Parkinson's disease-related mutations disrupt the dimerization of WD40 domain in LRRK2: a comparative molecular dynamics simulation study.
Li X; Ye M; Wang Y; Qiu M; Fu T; Zhang J; Zhou B; Lu S
Phys Chem Chem Phys; 2020 Sep; 22(36):20421-20433. PubMed ID: 32914822
[TBL] [Abstract][Full Text] [Related]
3. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ
Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661
[TBL] [Abstract][Full Text] [Related]
4. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
[TBL] [Abstract][Full Text] [Related]
5. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
Zhang X; Kortholt A
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
[TBL] [Abstract][Full Text] [Related]
7. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
Nguyen AP; Moore DJ
Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
[TBL] [Abstract][Full Text] [Related]
8. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE
Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344
[TBL] [Abstract][Full Text] [Related]
9. Insights into the Influence of Specific Splicing Events on the Structural Organization of
Vlachakis D; Labrou NE; Iliopoulos C; Hardy J; Lewis PA; Rideout H; Trabzuni D
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223621
[TBL] [Abstract][Full Text] [Related]
10. The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.
Huang X; Wu C; Park Y; Long X; Hoang QQ; Liao J
FASEB J; 2019 Apr; 33(4):4814-4823. PubMed ID: 30592623
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain.
Piccoli G; Onofri F; Cirnaru MD; Kaiser CJ; Jagtap P; Kastenmüller A; Pischedda F; Marte A; von Zweydorf F; Vogt A; Giesert F; Pan L; Antonucci F; Kiel C; Zhang M; Weinkauf S; Sattler M; Sala C; Matteoli M; Ueffing M; Gloeckner CJ
Mol Cell Biol; 2014 Jun; 34(12):2147-61. PubMed ID: 24687852
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
[TBL] [Abstract][Full Text] [Related]
13. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.
Deng J; Lewis PA; Greggio E; Sluch E; Beilina A; Cookson MR
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1499-504. PubMed ID: 18230735
[TBL] [Abstract][Full Text] [Related]
14. Allosteric inhibition of LRRK2, where are we now.
Soliman A; Cankara FN; Kortholt A
Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
[TBL] [Abstract][Full Text] [Related]
15. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
Park Y; Liao J; Hoang QQ
Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
[TBL] [Abstract][Full Text] [Related]
16. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
[TBL] [Abstract][Full Text] [Related]
17. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
[TBL] [Abstract][Full Text] [Related]
18. Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization.
Pathak P; Alexander KK; Helton LG; Kentros M; LeClair TJ; Zhang X; Ho FY; Moore TT; Hall S; Guaitoli G; Gloeckner CJ; Kortholt A; Rideout H; Kennedy EJ
ACS Chem Neurosci; 2023 Jun; 14(11):1971-1980. PubMed ID: 37200505
[TBL] [Abstract][Full Text] [Related]
19. A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover.
Deyaert E; Wauters L; Guaitoli G; Konijnenberg A; Leemans M; Terheyden S; Petrovic A; Gallardo R; Nederveen-Schippers LM; Athanasopoulos PS; Pots H; Van Haastert PJM; Sobott F; Gloeckner CJ; Efremov R; Kortholt A; Versées W
Nat Commun; 2017 Oct; 8(1):1008. PubMed ID: 29044096
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
